| Document |
Document Title |
|
WO/2022/091901A1 |
Component (1): at least one crude drug selected from the group consisting of longan aril, common fenugreek seed, lycium fruit, songaria cynomorium herb, black sesame, Dipsacus root, fortune's drynaria rhizome, flatstem milkvetch seed, bl...
|
|
WO/2022/092916A1 |
The present invention relates to an orally disintegrating film formulation comprising: tadalafil or a pharmaceutically acceptable salt thereof as an active ingredient; and hydroxypropyl cellulose and pullulan as film-forming polymers, an...
|
|
WO/2022/091375A1 |
The present invention provides a pharmaceutical composition for use in the treatment or prevention of peripartum cardiomyopathy, the pharmaceutical composition comprising an IL-6 inhibitor as an active ingredient.
|
|
WO/2022/092294A1 |
The present disclosure has solved problems associated with the TGF-β family or the like, which is called Myostatin/GDF-8 as a molecular mechanism and targeted by sarcopenia, by evaluating a pharmaceutical product in physiological aging ...
|
|
WO/2022/087496A1 |
A transdermal treatment for erectile dysfunction includes an aqueous solution having a plurality of excipients and a combination of papaverine, phentolamine mesylate and prostaglandin E1.
|
|
WO/2022/084889A1 |
The present invention relates to a SIRT1 activator for use in promoting and/or enhancing sperm capacitation process in mammals, a specific process for these cells. The disclosure also relates to a compound and a kit comprising the SIRT1 ...
|
|
WO/2022/086042A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of poor ovarian responders caused by aging, comprising, as an active ingredient, a mixed medicinal herb extract consisting of Rehmannia glutinos...
|
|
WO/2022/079684A1 |
The present invention relates to topical or injection compositions for use in the treatment of conditions requiring tissue repair and regeneration in humans and animals, comprising autologous platelet concentrates (APCs) and a colostrum ...
|
|
WO/2022/076145A1 |
A beverage unit and method to provide the beverage unit, are disclosed herein. The beverage unit comprising: at least 1 gram of d-mannose; at least 6 ounces of liquid, wherein the at least 1 gram of d-mannose is dissolved and combined wi...
|
|
WO/2022/074053A1 |
A foam inhalation device (874) for dispensing a foam to be inhaled by a user. The inhalation device (874) comprises a foam-generating component for generating the foam, an outlet (882) for dispensing the foam to the user, and a fluid flo...
|
|
WO/2022/071484A1 |
The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also...
|
|
WO/2022/069956A1 |
An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability.
|
|
WO/2022/071242A1 |
The present invention provides: a method of predicting the anticancer drug resistance and/or prognosis in a kidney cancer patient, said method comprising a step for evaluating the expression of Largen in the kidney cancer tissue of a sub...
|
|
WO/2022/067566A1 |
A pyrimidinedione compound containing a saturated oxygen-containing heterocyclic group and the use thereof, and a pharmaceutical composition comprising such compounds, which can be used as a gonadotropin releasing hormone receptor antago...
|
|
WO/2022/070483A1 |
The purpose of the present invention is to provide: a therapeutic drug for therapy-resistant cancer resistant to hormone therapy; and a therapeutic method. This pharmaceutical composition is for treatment of prostate cancer and contain...
|
|
WO/2022/067573A1 |
belonging to the technical field of pharmaceuticals, relating to a sulfonamide-substituted heteroaryl pyrimidinedione compound and use thereof, and a pharmaceutical composition containing said compound, which can act as gonadotropin-rele...
|
|
WO/2022/067382A1 |
Disclosed herein are methods for treating a mammalian teat, udder or breast, or protecting a teat, udder or breast from infection, comprising applying to the teat, udder or breast of a mammal a hygiene-maintaining composition comprising ...
|
|
WO/2022/058951A1 |
The present invention relates to luteinising hormone (LH) or to a molecule having LH-like activity or to a composition comprising it for use in inducing the activation, and/or the maturation of primordial and/or primary follicles in an i...
|
|
WO/2022/060334A1 |
The invention relates to a sexual health product composition, which comprises the fibers enabling the growth of the beneficial bacteria in the body and/or increasing the activity of the same, is beneficial for the skin, and also has the ...
|
|
WO/2022/054778A1 |
[Problem] To provide a sperm motility improving agent that is highly safe and that can effectively improve sperm motility. [Solution] A sperm motility improving agent containing a nicotinamide mononucleotide as an active ingredient.
|
|
WO/2022/056368A1 |
The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetra
hydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-
1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, (Compound A...
|
|
WO/2022/052605A1 |
Provided are a method for enhancing the secretion function of mesenchymal stem cells and the use thereof. By means of using hyaluronic acid sodium (HA) to pretreat umbilical cord mesenchymal stem cells in vitro, the secretion function of...
|
|
WO/2022/049280A1 |
The present invention relates to a peptide, or derivative thereof, having length equal to or lower than (30) amino acids, and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, for u...
|
|
WO/2022/047840A1 |
The present application pertains to the technical field of animal husbandry and veterinary medicine, and discloses a compound amino acid solution for an animal, a preparation method therefor, and an application thereof. The compound amin...
|
|
WO/2022/040896A1 |
A multi-drug delivery system includes a first capsule including a first capsule body that includes a first interior, and a first tablet and a second tablet within the first interior. The first tablet includes a first drug, and the second...
|
|
WO/2022/045211A1 |
The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopaus...
|
|
WO/2022/046870A1 |
Disclosed are methods to prevent an occurrence of a high-grade serous ovarian cancer and/or breast cancer in a subject by administering a therapeutically effective amount of an antiprogestin to the subject.
|
|
WO/2022/045513A1 |
The present invention relates to a composition for preventing or treating climacteric symptoms, comprising Lactobacillus fermentum. Particularly, the present invention relates to a food composition for preventing or alleviating climacter...
|
|
WO/2022/032484A1 |
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof....
|
|
WO/2022/034209A1 |
The invention relates to a new modified release oral pharmaceutical form comprising 17α- cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) and 17aα-ethinylestradiol (ethynyl estradiol), its method of production and its medical ...
|
|
WO/2022/027122A1 |
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...
|
|
WO/2022/027953A1 |
Disclosed is the use of C188-9, Venetoclax, and Bumetanide in a drug for fibrotic diseases. From a clinical view, an RNA recognition motif (RRM) region of the LARP6 protein is used as a docking target, and is subjected to computer virtua...
|
|
WO/2022/028547A1 |
Provided in the present invention are a class of bifunctional compounds for targeting and degrading an IRAK4 kinase protein, a pharmaceutical composition and a preparation method therefor. The compound of the present invention can not on...
|
|
WO/2022/025150A1 |
Disclosed is a therapeutic agent for breast cancer, said therapeutic agent comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin
-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxam
ide or a pharmacologically ac...
|
|
WO/2022/023762A1 |
The present invention relates to compounds for use in the delaying of labour and/or inhibition of uterine contractions in pre-term pregnant subjects. Such compounds include selective prostaglandin EP2 receptor agonists which specifically...
|
|
WO/2022/025204A1 |
The present disclosure provides an anti-EpoR peptide for use in the treatment of a disease such as cancer. In the description, a peptide which has the structure: -[SCHFGPLTWVCK]- and which is intended to be used for antagonizing an Epo h...
|
|
WO/2021/249913A9 |
The present invention relates to Map4K1 inhibitors of formula (I), to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compound...
|
|
WO/2022/017515A1 |
Provided in the present application are a diarylamine compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula 1; R1 is selected from an alkyl group of C1-12, an alkoxy group...
|
|
WO/2022/016752A1 |
An endometriosis lesion-targeted nano-delivery system, and a preparation method therefor and the use thereof. The delivery system comprises a hydrophobic inner core, which is located at the center, a lipid monomolecular layer around the ...
|
|
WO/2022/016375A1 |
An ectopic endometrium recognition polypeptide, and a derivative and the use thereof, which belong to the field of medical cell biology. The ectopic endometrium recognition polypeptide comprises a combination of one or more of the follow...
|
|
WO/2022/018716A1 |
Provided herein are an intravaginal delivery device comprising a plurality of distinct hydrogel layers, and methods of using same for treating a disease or disorder.
|
|
WO/2022/013430A1 |
The present invention relates to new glycolipids derivatives of Formula (I) and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. The present invention further relat...
|
|
WO/2022/014654A1 |
The present invention provides: a therapeutic and/or prophylactic agent for African swine fever (ASF) that contains 5-aminolevulinic acid (ALA), a derivative thereof or a salt of the same; and a therapeutic and/or prophylactic method for...
|
|
WO/2022/009170A1 |
The present invention relates to a novel isolated and characterised bacterial strain belonging to the species Lacticaseibacillus rhamnosus, to compositions thereof and to the use thereof in the treatment of genitourinary infections and/o...
|
|
WO/2022/009863A1 |
The present invention relates to a treatment agent for various diseases of the nervous system and mental illnesses which contains the compound represented in formula (1) or a pharmaceutically acceptable salt thereof as the active compone...
|
|
WO/2022/008707A1 |
The present invention refers to a biomass of T. chuii and a pharmaceutical composition comprising a biomass of T. chuii for use in the treatment of infertility in a male subject. It also refers to a method for increasing the quality of t...
|
|
WO/2022/002336A1 |
The present invention relates to a method for determining a likely effect of a treatment to improve male fertility using an antagonist or inhibitor of RANKL based on levels of AMH or Inhibin B in a biological sample such as serum or semi...
|
|
WO/2022/003259A1 |
An automated system (100) for processing physiological parameter measurements for providing an assessment of a medical risk. It comprises a model (106) previously built by machine learning to provide an idiopathic infertility score (S) o...
|
|
WO/2021/261490A1 |
The present invention addresses the problem of acquiring a promoter that promotes the synthesis and secretion of testosterone without any side effects. The present inventors searched for materials having significantly high ability to pro...
|
|
WO/2021/261341A1 |
[Problem] To provide a new use for a processed product of a plant of the genus Phyllanthus. [Solution] Provided are a composition for inhibiting PDE5 activity, a composition for improving erectile function, and a composition for improvin...
|
